Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

NCT04925609 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Large Cell Lymphoma, ALK-Positive
Inflammatory Myofibroblastic Tumor
Other Solid Tumor

Interventions

DRUG: Brigatinib

Sponsor

Princess Maxima Center for Pediatric Oncology

Collaborators

[object Object]